Editas Medicine, Inc. (EDIT) is a leading genetic medicine company, pioneering transformative therapies that utilize advanced genome editing technologies. Founded in 2013 and based in Cambridge, Massachusetts, Editas Medicine has positioned itself at the forefront of a revolution in medicine with a clear mandate: to translate breakthroughs in gene editing technologies, such as CRISPR and TALENs, to design and develop curative therapies that treat genetically-defined diseases.
Editas Medicine is focused on serving patients who suffer from debilitating genetic disorders which are currently untreatable. The company is built around bringing this mission to life, by developing medicines that enable precise editing of genetic material, with the aim of eliminating disease-causing abnormalities at the DNA level.
The firm’s unique approach is based on CRISPR/Cas9 and CRISPR/Cpf1 gene editing technology platforms. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized the field of genetic engineering, by enabling targeted and highly precise alterations to specific genes within an organism. This technology holds the potential not only to correct genetic defects, but also to treat a wide array of diseases, by modifying DNA sequences.
Editas Medicine is developing a diverse portfolio of treatments with the hope of improving the lives of patients across multiple therapeutic areas including ocular diseases, cancer immunotherapies, and disorders arising from viral infections.
One of Editas Medicine’s most notable programs is its research into treating Leber Congenital Amaurosis type 10 (LCA10), a rare genetic disease that leads to blindness. The company has developed EDIT-101, an experimental gene therapy, which is the first in-vivo CRISPR medicine to be administered to a patient in a clinical trial.
The global genetic medicine landscape is highly competitive and rapidly evolving, and Editas Medicine faces the challenge of both developing successful therapies and navigating regulatory complexities. Yet, with its robust research and development capabilities, and commitment to leveraging the therapeutic potential of gene-editing technologies, Editas Medicine has positioned itself as a serious contender in the race to bring genetic medicine to those who need it the most.
As at the forefront of gene-editing technology, Editas Medicine's impact on future therapies and cure of genetic disorders is significant. The company’s work could potentially rewrite the script for treating genetic diseases, affirming their dedication to transforming lives through the power of genome editing.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Guggenheim has upgraded Editas Medicine (EDIT) stock to Buy from Neutral. The upgrade is based on the potential of the company's hyperlipidemia therapy, EDIT-401, which offers a novel gene editing approach for treating severely high blood cholesterol. Editas is currently preparing to advance this therapy.
Guggenheim has upgraded Editas Medicine (EDIT) to a "Buy" rating from "Neutral," setting a new price target of $5. The article mentions that Editas Medicine currently has an average analyst rating of overweight with a mean price target of $4.88. Access to the full report requires a premium subscription.
Editas Medicine plans to begin patient dosing in 2026 for its lead gene-editing therapy, EDIT-401, targeting high LDL cholesterol. This in vivo CRISPR therapy aims to increase LDL receptor production, with non-human primate studies showing a 90% reduction in LDL cholesterol. The company, which had $212 million in cash as of Q2, expects initial safety data in Q1 2027 and broader results later that year, anticipating funding operations into the second half of 2028.
Opaleye Management Inc. significantly increased its stake in Editas Medicine, Inc. (NASDAQ:EDIT) during the second quarter, purchasing 1,934,933 additional shares to own a total of 3,861,930 shares, valued at approximately $12.5 million. This investment now represents 2.51% of Editas Medicine and 1.1% of Opaleye Management's portfolio. Editas Medicine, a clinical-stage biotechnology company, maintains a "Moderate Buy" consensus rating from analysts, with an average target price of $6.00, and recently surpassed quarterly revenue and EPS estimates.
Editas Medicine is preparing to initiate the first human trial in Australia for EDIT-401, a CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia. The therapy, delivered via a single intravenous infusion, has shown promising results in non-human primates, significantly reducing LDL cholesterol and increasing LDL receptor expression. The company expects to share human safety data in Q1 2027 and initial efficacy results later that year, with sufficient cash reserves to fund development into the second half of 2028.
Seven Fleet Capital Management LP has acquired a new position in Editas Medicine, Inc. (NASDAQ:EDIT), purchasing 1.33 million shares valued at $4.31 million. This makes Editas Medicine its 28th largest holding, representing 0.7% of the fund's portfolio. Institutional ownership in Editas Medicine remains high at 71.9%, with other firms also increasing their stakes, while analysts maintain a "Moderate Buy" rating with a $6.00 price target.